During the poster discussion session on colon and anal cancer, Prof Dr Eric Van Cutsem from the University Hospital Gasthuisberg, Leuven, offered valuable insights that were informative and relevant.
One of the studies presented was the SOLSTiCE study by Professor Thierry André from Hôpital Saint-Antoine in Paris, France. This study aimed to compare trifluridine/tipiracil +bevacizumab with capecitabine + bevacizumab as first-line treatment options for patients with unresectable metastatic CRC who were not eligible for intensive chemotherapy.
Another study discussed was the CodeBreaK 101 phase, which focused on the safety and efficacy of treating previously treated KRAS G12C-mutated metastatic colorectal cancer with the combination of sotorasib plus panitumumab and FOLFIRI.
Professor Van Cutsem also acknowledged Professor Miriam Koopman and the Dutch researchers for their presentation of the data from the CAIRO4 study, which investigated the potential benefits of upfront palliative resection of the primary tumour followed by systemic therapy versus systemic therapy alone in a phase III randomized study.
The OPRA trial, which reported on the long-term organ preservation and oncologic outcomes in patients with locally advanced rectal cancer treated with neoadjuvant therapy, was also discussed. Finally, Professor Van Cutsem reflected on the hypothesis of circulating tumour DNA as an early predictor of recurrence in the curative setting in colorectal cancer, summarizing several studies that explored this topic.
With the educational support of:
